Phaseline

Companies › Frontera Therapeutics

Frontera Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 4 Phase 1; Ophthalmology; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FT-003
Gene therapy for diabetic macular edema; delivers intraocular protein with durable therape
–Phase 1Diabetic Macular Edema; Neovascular Age-related Macular DegenerationMay 2028
FT-001
Subretinal AAV5-delivered RPE65 gene therapy
RPE65Phase 1Biallelic RPE65 Mutation-associated Retinal DystrophyNov 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05916391FT-003Phase 1Diabetic Macular EdemaOphthalmologyMay 2028
NCT06492863FT-003Phase 1Neovascular Age-related Macular DegenerationOphthalmologyOct 2028
NCT06492876FT-003Phase 1Diabetic Macular EdemaOphthalmologyNov 2028
NCT05858983FT-001Phase 1Biallelic RPE65 Mutation-associated Retinal DystrophyOphthalmologyNov 2029

Targets

RPE65 (1)

Companies with the same targets

Innostellar Biotherapeutics Spark Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.